Early breast cancer: multimodal de-escalation strategies to reduce treatment burden safely

59 Visioni

  • Grazie! Condividilo con i tuoi amici!

    Non hai gradito questo video. Grazie per il feedback!

admin
Published
In this latest episode of the VJOncoAlert Journal Club, Icro Meattini, MD, University of Florence, Florence, Italy, discusses multimodal de-escalation strategies in early breast cancer treatment, based on a recently published ASCO educational book paper. Dr Meattini emphasizes that while excellent cure rates set high standards, therapy de-escalation must occur within a comprehensive multimodal framework to avoid escalating other treatments. Key points include: sentinel node biopsy can be safely omitted in select hormone receptor-positive patients after neoadjuvant therapy; surgical and radiation adaptations based on systemic treatment response require quality assurance; modern targeted agents necessitate radiotherapy timing adjustments; and gene expression tools enable chemotherapy omission in intermediate-risk patients.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Categoria
Oncology
Commenta per primo questo video.

Prossimo